Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1JS6

Crystal Structure of DOPA decarboxylase

1JS6 の概要
エントリーDOI10.2210/pdb1js6/pdb
関連するPDBエントリー1JS3
分子名称DOPA decarboxylase, PYRIDOXAL-5'-PHOSPHATE (3 entities in total)
機能のキーワードdopa decarboxylase, carbidopa, parkinson's disease, vitamin b6, lyase
由来する生物種Sus scrofa (pig)
タンパク質・核酸の鎖数2
化学式量合計108498.63
構造登録者
Burkhard, P.,Dominici, P.,Borri-Voltattorni, C.,Jansonius, J.N.,Malashkevich, V.N. (登録日: 2001-08-16, 公開日: 2001-10-26, 最終更新日: 2025-03-26)
主引用文献Burkhard, P.,Dominici, P.,Borri-Voltattorni, C.,Jansonius, J.N.,Malashkevich, V.N.
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Nat.Struct.Biol., 8:963-967, 2001
Cited by
PubMed Abstract: DOPA decarboxylase (DDC) is responsible for the synthesis of the key neurotransmitters dopamine and serotonin via decarboxylation of L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan, respectively. DDC has been implicated in a number of clinic disorders, including Parkinson's disease and hypertension. Peripheral inhibitors of DDC are currently used to treat these diseases. We present the crystal structures of ligand-free DDC and its complex with the anti-Parkinson drug carbiDOPA. The inhibitor is bound to the enzyme by forming a hydrazone linkage with the cofactor, and its catechol ring is deeply buried in the active site cleft. The structures provide the molecular basis for the development of new inhibitors of DDC with better pharmacological characteristics.
PubMed: 11685243
DOI: 10.1038/nsb1101-963
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.6 Å)
構造検証レポート
Validation report summary of 1js6
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon